行业质量体系在药品CGMP法规方面的指导原则(中文)
VIP免费
CGMP
CDER
CBER
CVM
ORA
2006 9
CGMP
CGMP
HFD-240
5600
20857
301-827-4573
http://www.fda.gov/cder/guidance/index.htm
HFM-40
1401
20852-1448 http://www.fda.gov/cber/guidelines.
htm.800-835-4709 301-827-180
HFV-12
7519 2085
301-827-380
http://www.fda.gov/cvm/guidance/published.html
CDER
CBER
CVMORA
2006 9 CGMP
Contains Nonbinding Recommendations
. ....................................................................................................................................... 1
II. ............................................................................................................................ 1
A. .....................................................................................................................................................................1
B. .........................................................................................................................................................2
C. .........................................................................................................................................................3
D. .............................................................................................................................................4
III. CGMPS ........................................................................................... 4
A. ......................................................................................................................................................................4
B. .............................................................................................................................4
C. .....................................................................................................................................................5
D. CAPA...............................................................................................................................5
E. .............................................................................................................................................................5
F. .............................................................................................................................................................5
G. ..................................................................................................................................................6
IV. ....................................................................................................................... 8
A. .............................................................................................................................................................8
1. .........................................................................................................................................................8
2. ............................................................................................................................................................9
3. .......................................................................................................................9
4. .....................................................................................................................................10
5. ...........................................................................................................................................................10
B. ...................................................................................................................................................................12
1. ...........................................................................................................................................................12
2. ...........................................................................................................................................................13
3. ........................................................................................................................................................13
4. ..................................................................................................................................................14
C. ..................................................................................................................................................................15
1. ..........................................................................................................................15
2. ..........................................................................................................................................................16
3. .............................................................................................................................................17
4. ...................................................................................................................................................19
D. ............................................................................................................................................................21
1. ......................................................................................................................................21
2. ....................................................................................................................................................21
3. ..................................................................................................................................................22
4. ............................................................................................................................................................22
摘要:
展开>>
收起<<
oTCGMPlvOSelLNcSWVSkuNQlOgRToTvwctoTNTxzvNCDERuriR6TO0xzvNCBERQoNCVMvNRRQlORA2006t9goTuNtCGMPoTCGMPlvOSelLNcSWYvRogSNNNnSSWNlRQloTOoYHFD240oTNTxzvNToTvwct95600SlQpWQK20857Su53018274573httpwwwfdagovcderguidanceindexhtmb0WNRQluriR6TO0xzvNHFM40R6UFSORToTvwct1401WQKYSWQKlQp208521448httpwwwfdagovcberguid...
声明:如果您的权利被侵害,请联系我们的进行举报。
相关推荐
-
GB∕T 25915.2-2021 洁净室及相关受控环境 第2部分:洁净室空气粒子浓度的监测
2024-04-17 999+ -
GB∕T 25915.3-2024洁净室及相关受控环境 第3部分:检测方法VIP免费
2024-08-09 127 -
(高清)GB∕T 25915.3-2024 洁净室及相关受控环境第3部分:检测方法VIP免费
2025-08-27 999+ -
GB∕T 16886.1-2025医疗器械生物学评价 第1部分 风险管理过程中生物学安全性评价的要求和通用原则(草案稿)VIP免费
2025-09-02 834 -
GB∕T 16886.11-2021 医疗器械生物学评价 第11部分:全身毒性试验VIP免费
2025-09-02 866 -
GB∕T 191-2025 包装储运图示标志(征求意见稿)VIP免费
2025-09-29 999+ -
GB∕T 19000-2016 质量管理体系 基础和术语(高清)VIP免费
2025-10-27 999+ -
GB∕T 19001-2016 质量管理体系要求
2025-10-27 999+ -
GB∕T 16292-2025 医药工业洁净室(区)悬浮粒子的测试方法VIP免费
2025-10-29 999+ -
GB∕T 16292《医药工业洁净室(区)悬浮粒子的测试方法》2010版和2025版对比分析(逐条对比)VIP免费
2025-10-30 579
作者:冒牌货
分类:专业资料
价格:150质量币
属性:32 页
大小:6.42MB
格式:PDF
时间:2025-12-04

